https://www.zacks.com/stock/news/2240226/allogene-allo-inks-deal-with-arbor-bio-for-crispr-technology?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240226
Mar 13, 2024 - Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
zc:-2554321397242822348
0
https://www.zacks.com/stock/news/2245547/opko-health-opk-and-entera-bio-announce-data-for-glp-2?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245547
Mar 25, 2024 - OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
zc:85702958607531946
0
https://www.zacks.com/stock/news/2246721/earnings-preview-bluebird-bio-blue-q4-earnings-expected-to-decline?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2246721
Mar 27, 2024 - Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:2051034304120402783
0
https://www.zacks.com/stock/news/2246863/kronos-bio-kron-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2246863
Mar 27, 2024 - Kronos Bio (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zc:-31642677059271945
0
https://www.zacks.com/stock/news/2246798/why-is-theravance-bio-tbph-down-9-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2246798
Mar 27, 2024 - Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
zc:-8949102884134676952
0
https://www.zacks.com/stock/news/2250503/does-kala-bio-kala-have-the-potential-to-rally-152-83-as-wall-street-analysts-expect?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2250503
Apr 04, 2024 - The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
zc:-7023726703701195420
0
https://www.zacks.com/stock/news/2251859/down-63-39-in-4-weeks-here-s-why-gritstone-bio-grts-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2251859
Apr 08, 2024 - Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zc:-1544491553204050899
0
https://www.zacks.com/stock/news/2252481/here-s-why-you-should-invest-in-entera-bio-entx-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252481
Apr 09, 2024 - Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.
zc:-1706741624505731906
0
https://www.zacks.com/stock/news/2253383/does-belite-bio-blte-have-the-potential-to-rally-41-14-as-wall-street-analysts-expect?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2253383
Apr 10, 2024 - The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zc:-6158566842664947001
0
https://www.zacks.com/stock/news/2263665/entera-bio-ltd-entx-stock-slides-as-market-rises-facts-to-know-before-you-trade?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2263665
Apr 26, 2024 - The latest trading day saw Entera Bio Ltd. (ENTX) settling at $1.98, representing a -1% change from its previous close.
zc:6031178259663694975
0